皮下注射concizumab预防治疗在伴抑制物A型及A/B型血友病中的长期疗效与安全性
本文报告explorer4和explorer5两项2期试验扩展部分结果,评估每日一次皮下注射concizumab预防治疗在伴抑制物A/B型血友病及不伴抑制物重型A型血友病中的长期安全性与疗效。主要+扩展部分估计ABR在explorer4为4.8、explorer5为6.4,自发性ABR分别为1.8和2.1;多数不良事件为轻度,无死亡、退出事件或血栓栓塞事件。
要点
- 每日一次皮下注射concizumab预防治疗在血友病各亚型中显示长期疗效与安全性。
- 主要+扩展部分估计ABR:explorer4为4.8,explorer5为6.4。
- 抗药抗体发生率为25%,低滴度且一过性,多数无临床效应。
核心结论
- 两项2期试验主要+扩展部分结果与主要部分一致,支持每日一次皮下注射concizumab作为血友病各亚型的治疗选择;正在进行的3期试验将进一步评估。
研究设计与样本
- 两项2期试验的扩展部分,包括主要部分(≥24周)和扩展部分(52-102周)。
- 患者接受concizumab 0.15 mg/kg,若12周内发生≥3次治疗性自发性出血事件,可剂量递增至0.20或0.25 mg/kg。
- 暴露于concizumab的患者:不伴抑制物重型A型血友病36例,伴抑制物A型血友病15例,伴抑制物B型血友病10例。
主要发现
- 主要+扩展部分末次剂量水平估计ABR在explorer4为4.8(95%CI 3.2-7.2),在explorer5为6.4(95%CI 4.1-9.9)。
- 自发性ABR在explorer4为1.8(95%CI 1.2-2.6),在explorer5为2.1(95%CI 1.3-3.3)。
- 多数不良事件为轻度,无死亡、导致退出的事件或血栓栓塞事件。
- 25%的患者出现抗药抗体,低滴度且一过性,多数病例未观察到临床效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite current therapies, there remains an unmet need for treatment for patients with hemophilia. The main parts of two phase 2 trials established clinical proof-of-concept for once-daily, subcutaneous concizumab prophylaxis in patients with hemophilia A/B with inhibitors (HAwI/HBwI; explorer4) and severe hemophilia A without inhibitors (HA; explorer5). Here, we present results from extension parts of these trials, included to evaluate longer term safety and efficacy. Both trials included main (≥24 weeks) and extension (52-102 weeks) parts, with patients receiving concizumab 0.15 mg/kg with potential dose escalation to concizumab 0.20 or 0.25 mg/kg if they experienced ≥3 treated spontaneous bleeding episodes within 12 weeks. Endpoints included annualized bleeding rate (ABR), adverse events (AEs), and occurrence of antidrug antibodies. Thromboembolic events were AEs of special interest. Thirty-six patients with HA, 15 with HAwI, and 10 with HBwI were exposed to concizumab. Estimated ABRs during the main + extension parts at last dose level were 4.8 (95% confidence interval [CI], 3.2-7.2) and 6.4 (95% CI, 4.1-9.9) in explorer4 and explorer5, respectively (spontaneous ABRs were 1.8 [95% CI, 1.2-2.6] and 2.1 [95% CI, 1.3-3.3]). Most AEs were mild, with no deaths, events leading to withdrawal, or thromboembolic events. Anti-drug antibodies developed in 25% of patients and were low titer and transient, with no observed clinical effect in most cases. Results of the main + extension parts of these trials were consistent with results of the main parts. Ongoing phase 3 trials will further evaluate concizumab as a once-daily, subcutaneous treatment across hemophilia subtypes. These trials were registered at www.clinicaltrials.gov as #NCT03196284 and #NCT03196297.
引用
- Shapiro AD, Angchaisuksiri P, Astermark J, et al. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022. PMID: 35290453. doi:10.1182/bloodadvances.2021006403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。